100% enrollment had 60 days before trial was finished + time to collate, analyze, and publish final results before anything was really known as to trial results. Not positive but top line results showing general success of trial should be much earlier after the end of the 60 days.
100% enrollment was like horses having all entered the starting gate for a race, end of trial (60 days later) is when the horses cross the finish line. You still have the officials reviewing the photo finish and any possible challenges to the order of finish before the "official finish" is declared, but for all practical purposes the fans know who won when the horses crossed the line.
Once the trial is officially finished, we are 60 days closer to top line and finalized published results + we will have had the Virology Conference information, we will have only about 3 weeks until the Military Health Research Symposium presentation, and most likely we will be within weeks of getting some major grants from various sources as the full understanding of the strength and breadth of the Brilacidin spectrum of indications becomes understood. I also expect MAJOR, MAJOR media attention paid to Brilacidin/IPIX starting in August.
So why would one expect these two time points to have the same share price action?
I don't think people yet understand the impact that the Military Health Research presentation will have for Brilacidin rising to the top as one of the most, if not, primary drugs for being able to defeat biological weapons targeting the USA.
100% enrollment did NOTHING as to bringing in new institutional buying whereas after trial finished I believe we will see quite a bit in August. If one is still buying the BS being played daily about the "high risk"then one could lose out on a fortune that is right around the corner.
If there were many still really doubting the true value of Brilacidin, there would not be presentations scheduled in July and August that will highlight:
"New data supporting Brilacidin’s broad spectrum antiviral properties will be presented at the 2021 MHSRS conference, as well as during a separate oral presentation on Brilacidin to be delivered at the American Society of Virology’s 40th Annual Meeting, to be held in July."
NEW DATA - Brilacidin even more powerful than what we know today. So we know 'in vitro' results going great guns and safety is pretty much a given based on clinical trial results to date.
News 
Market Data 
Discover 
AI
